Tuberculosis and Respiratory Diseases

  • 제71권3호
  • /
  • Pages.163-171
  • /
  • 2011
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

간질성 폐질환

Interstitial Lung Disease

  • 정만표 (성균관대학교 의과대학 내과학교실 삼성서울병원 호흡기내과)
  • Chung, Man-Pyo (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2011.04.19
  • 심사 : 2011.04.21
  • 발행 : 2011.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Recently published articles on interstitial lung disease (ILD) have focused on the accurate diagnosis of idiopathic pulmonary fibrosis (IPF), serum biomarkers, acute exacerbation of IPF, the prognostic factors of ILD and the trial of new treatment. In particular, reports on the serum biomarkers such as CC-chemokine ligand 18, surfactant protein, circulating fibrocytes, and acute exacerbation of IPF are sufficient to be mentioned here. Pirfenidone therapy is the most important trial for the treatment of IPF. Other newer treatment trials such as interferon-gamma, sildenafil and imatinib have been reported to be unsuccessful. On the other hand, the sirolimus trial for lymphangioleiomyomatosis is promising. Combined pulmonary fibrosis and emphysema and IgG4-related disease are established to be the new disease entities of ILD.

키워드

참고문헌

  1. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010; 298:L715-31. https://doi.org/10.1152/ajplung.00361.2009
  2. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010;123: 304-11. https://doi.org/10.1016/j.amjmed.2009.07.033
  3. Rottoli P, Bargagli E, Landi C, Magi B. Proteomic analysis in interstitial lung diseases: a review. Curr Opin Pulm Med 2009;15:470-8. https://doi.org/10.1097/MCP.0b013e32832ea4f2
  4. Verma S, Slutsky AS. Idiopathic pulmonary fibrosis-- new insights. N Engl J Med 2007;356:1370-2. https://doi.org/10.1056/NEJMcibr070490
  5. Borchers AT, Chang C, Keen CL, Gershwin ME. Idiopathic pulmonary fibrosis-an epidemiological and pathological review. Clin Rev Allergy Immunol 2011;40: 117-34. https://doi.org/10.1007/s12016-010-8211-5
  6. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63 Suppl 5:v1-58. https://doi.org/10.1136/thx.2008.101691
  7. Dempsey OJ, Kerr KM, Remmen H, Denison AR. How to investigate a patient with suspected interstitial lung disease. BMJ 2010;340:c2843. https://doi.org/10.1136/bmj.c2843
  8. Raghu G, Nicholson AG, Lynch D. The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias. Eur Respir Rev 2008;17: 108-15. https://doi.org/10.1183/09059180.00010902
  9. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40. https://doi.org/10.1164/rccm.201006-0894CI
  10. Galvin JR, Frazier AA, Franks TJ. Collaborative radiologic and histopathologic assessment of fibrotic lung disease. Radiology 2010;255:692-706. https://doi.org/10.1148/radiol.10090717
  11. Wells AU. The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev 2010;19:237-41. https://doi.org/10.1183/09059180.00005510
  12. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31:1357-67. https://doi.org/10.1183/09031936.00171307
  13. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132:1652-8.
  14. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636-43. https://doi.org/10.1164/rccm.200703-463PP
  15. Schwartz DA. Genetic analysis of sporadic and familial interstitial pneumonia. Proc Am Thorac Soc 2008;5: 343-7. https://doi.org/10.1513/pats.200710-158DR
  16. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010;138:251-6. https://doi.org/10.1378/chest.10-0194
  17. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 2010;12:213. https://doi.org/10.1186/ar3097
  18. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009;33:882-96. https://doi.org/10.1183/09031936.00152607
  19. Fischer A, Brown KK, Frankel SK. Treatment of connective tissue disease-associated interstitial lung disease. Clin Pulm Med 2009;16:74-80. https://doi.org/10.1097/CPM.0b013e31819b5400
  20. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008;133:507-16. https://doi.org/10.1378/chest.07-0898
  21. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35:14-26. https://doi.org/10.1183/09031936.00076209
  22. Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med 2009;15:491-8. https://doi.org/10.1097/MCP.0b013e32832ea51c
  23. Chung MP, Yi CA, Lee HY, Han J, Lee KS. Imaging of pulmonary vasculitis. Radiology 2010;255:322-41. https://doi.org/10.1148/radiol.10090105
  24. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-81. https://doi.org/10.1164/rccm.201006-0865CI
  25. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011;139:174-82. https://doi.org/10.1378/chest.10-0188
  26. Maher TM. The diagnosis of idiopathic pulmonary fibrosis and its complications. Expert Opin Med Diagn 2008;2:1317-31. https://doi.org/10.1517/17530050802549484
  27. Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:832-7. https://doi.org/10.1164/rccm.200906-0959OC
  28. Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:1043-7. https://doi.org/10.1164/rccm.200808-1313OC
  29. Sverzellati N, Wells AU, Tomassetti S, Desai SR, Copley SJ, Aziz ZA, et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology 2010;254:957-64. https://doi.org/10.1148/radiol.0990898
  30. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009;136:23-30. https://doi.org/10.1378/chest.08-2572
  31. van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010;182:1419-25. https://doi.org/10.1164/rccm.200906-0953OC
  32. van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2010;23:515-20. https://doi.org/10.1016/j.pupt.2010.08.001
  33. Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG. Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res 2010;11:89. https://doi.org/10.1186/1465-9921-11-89
  34. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:717-23. https://doi.org/10.1164/rccm.200808-1201OC
  35. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, et al. Serum surfactant protein- A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009;135:1557-63. https://doi.org/10.1378/chest.08-2209
  36. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:588-94. https://doi.org/10.1164/rccm.200810-1534OC
  37. Moore BB. Fibrocytes as potential biomarkers in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:524-5. https://doi.org/10.1164/rccm.200812-1847ED
  38. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010;299:L3-7. https://doi.org/10.1152/ajplung.90637.2008
  39. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37:356-63. https://doi.org/10.1183/09031936.00159709
  40. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167-75. https://doi.org/10.1164/rccm.200810-1596OC
  41. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 2009;103:846-53.
  42. Huie TJ, Olson AL, Cosgrove GP, Janssen WJ, Lara AR, Lynch DA, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010;15:909-17. https://doi.org/10.1111/j.1440-1843.2010.01774.x
  43. Kondoh Y, Taniguchi H, Kataoka K, Kato K, Suzuki R, Ogura T, et al. Prognostic factors in rapidly progressive interstitial pneumonia. Respirology 2010;15:257-64. https://doi.org/10.1111/j.1440-1843.2009.01687.x
  44. Park IN, Jegal Y, Kim DS, Do KH, Yoo B, Shim TS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009;33:68-76. https://doi.org/10.1183/09031936.00158507
  45. Akira M, Inoue Y, Arai T, Okuma T, Kawata Y. Longterm follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax 2011;66:61-5. https://doi.org/10.1136/thx.2010.140574
  46. Lee JW, Lee KS, Lee HY, Chung MP, Yi CA, Kim TS, et al. Cryptogenic organizing pneumonia: serial highresolution CT findings in 22 patients. AJR Am J Roentgenol 2010;195:916-22. https://doi.org/10.2214/AJR.09.3940
  47. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009;14:723-8. https://doi.org/10.1111/j.1440-1843.2009.01547.x
  48. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis- interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372-8. https://doi.org/10.1164/rccm.201004-0622OC
  49. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009;136:1341-7. https://doi.org/10.1378/chest.08-2740
  50. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9. https://doi.org/10.1183/09031936.00005209
  51. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8. https://doi.org/10.1056/NEJMoa1002110
  52. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8. https://doi.org/10.1016/S0140-6736(09)60551-1
  53. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10. https://doi.org/10.1164/rccm.200906-0964OC
  54. Klingsberg RC, Mutsaers SE, Lasky JA. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology 2010;15:19-31. https://doi.org/10.1111/j.1440-1843.2009.01672.x
  55. Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, et al. Survival after bilateral versus single- lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 2009;151:767-74. https://doi.org/10.7326/0003-4819-151-11-200912010-00004
  56. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51. https://doi.org/10.1056/NEJMoa063564
  57. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93. https://doi.org/10.1183/09031936.05.00021005
  58. Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-5. https://doi.org/10.1378/chest.08-2306
  59. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010;35:105-11. https://doi.org/10.1183/09031936.00038709
  60. Shigemitsu H, Koss MN. IgG4-related interstitial lung disease: a new and evolving concept. Curr Opin Pulm Med 2009;15:513-6. https://doi.org/10.1097/MCP.0b013e32832ea509
  61. Shrestha B, Sekiguchi H, Colby TV, Graziano P, Aubry MC, Smyrk TC, et al. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol 2009;33:1450-62. https://doi.org/10.1097/PAS.0b013e3181ac43b6
  62. Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Kobayashi T, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 2009;251:260-70. https://doi.org/10.1148/radiol.2511080965
  63. Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. 2008 National survey of idiopathic interstitial pneumonia in Korea. Tuberc Respir Dis 2009;66:141-51. https://doi.org/10.4046/trd.2009.66.2.141
  64. Kim C, Jeong SH, Shim JJ, Cha SI, Son C, Chug MP, et al. Clinical features of pulmonary langerhans cell histiocytosis in Korea. Tuberc Respir Dis 2009;66:98- 103. https://doi.org/10.4046/trd.2009.66.2.98
  65. Byun MK, Kim DS, Kim YW, Chung MP, Shim JJ, Cha SI, et al. Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population. J Korean Med Sci 2010;25:393-8. https://doi.org/10.3346/jkms.2010.25.3.393
  66. Park HY, Nam HS, Chung MP, Jeong SH, Kim YJ, Cha SI, et al. A nationwide survey of lymphangioleiomyomatosis in Korea. J Korean Med Sci 2010;25:1182-6. https://doi.org/10.3346/jkms.2010.25.8.1182